Virios Therapeutics (NASDAQ:VIRI) Shares Down 3.2%

Virios Therapeutics, Inc. (NASDAQ:VIRI)’s share price dropped 3.2% on Tuesday . The stock traded as low as $0.88 and last traded at $0.92. Approximately 324,448 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 1,439,657 shares. The stock had previously closed at $0.95.

Virios Therapeutics Stock Down 3.2 %

The firm’s 50-day moving average price is $1.50 and its two-hundred day moving average price is $1.13. The firm has a market capitalization of $17.71 million, a PE ratio of -1.67 and a beta of 1.95.

Virios Therapeutics (NASDAQ:VIRI) last released its earnings results on Thursday, August 10th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). Equities research analysts forecast that Virios Therapeutics, Inc. will post -0.34 EPS for the current year.

Insider Activity at Virios Therapeutics

In related news, CEO Gregory Scott Duncan acquired 25,000 shares of the stock in a transaction that occurred on Thursday, August 17th. The shares were purchased at an average cost of $1.25 per share, with a total value of $31,250.00. Following the completion of the transaction, the chief executive officer now owns 57,461 shares of the company’s stock, valued at approximately $71,826.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 10.40% of the stock is currently owned by insiders.

Institutional Trading of Virios Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC bought a new position in Virios Therapeutics during the third quarter worth $67,000. Susquehanna International Group LLP increased its position in Virios Therapeutics by 343.3% during the first quarter. Susquehanna International Group LLP now owns 161,811 shares of the company’s stock worth $59,000 after acquiring an additional 125,311 shares during the period. Vanguard Group Inc. increased its position in Virios Therapeutics by 63.4% during the first quarter. Vanguard Group Inc. now owns 241,666 shares of the company’s stock worth $1,082,000 after acquiring an additional 93,800 shares during the period. Envestnet Asset Management Inc. increased its position in Virios Therapeutics by 576.3% during the fourth quarter. Envestnet Asset Management Inc. now owns 109,196 shares of the company’s stock worth $26,000 after acquiring an additional 93,050 shares during the period. Finally, Geode Capital Management LLC increased its position in Virios Therapeutics by 144.3% during the second quarter. Geode Capital Management LLC now owns 147,269 shares of the company’s stock worth $203,000 after acquiring an additional 86,983 shares during the period. 10.96% of the stock is currently owned by institutional investors and hedge funds.

Virios Therapeutics Company Profile

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.